News | December 07, 2025
Biocon to merge Biocon Biologics in $5.5 billion deal
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
The topical fluralaner solution is cleared for the prevention and treatment of new world screwworm infestation
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Senores Pharmaceuticals is poised to accelerate its presence in the Asia-Pacific region
The BlueSeal Horizon 3.0T platform incorporates advanced magnet technology
Grant of Permission to manufacture and market FDC of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/20mg)
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
Patients can now get the starting 2.5 mg dose for $299 per month
The study, titled “A Large-Scale Efficacy Trial of a Resilience Training Program for First Responders,” will enroll 800 first responders in New York and Texas
The audit was completed with zero critical and zero major observations
Subscribe To Our Newsletter & Stay Updated
